Natalizumab is associated with no evidence of disease activity and with improvement in disability and cognitive performance in anti-JC virus seronegative patients with early relapsing-remitting multiple sclerosis: STRIVE 4-year results

J. Perumal,R. J. Fox, R. Balabanov, L. Balcer, S. Galetta,P. Read,R. Su,D. Campagnolo, C. Hotermans,L. Lee

MULTIPLE SCLEROSIS JOURNAL(2019)

引用 1|浏览1
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要